人工智能机器人在核医学病房中的初步应用与展望

人工智能（AI）是指由人制造出来的机器所表现出来的智能，也是一门用于模拟、延伸和扩展人的智能的理论、方法、技术及应用系统的新兴科学。AI可以应用在诸多领域，其与机器人的结合应用非常广泛，并较早应用于医学领域。但是，AI应用于核医学病房的时间相对较晚，仍有很多问题需要改进。针对临床上常用的AI机器人在核医学病房中的应用现状，笔者从入院宣教、环境监测、查房和消毒等4个主要功能方面进行了综述。笔者通过探讨其所涉及的亟待解决的问题，指出了需要进一步研究发展的方向，旨在推动核素诊疗的长足发展。     

Aberrant functional and effective connectivity of the frontostriatal network in unilateral acute tinnitus patients with hearing loss

Brain Imaging and Behavior - The present study combined resting-state functional connectivity (FC) and Granger causality analysis (GCA) to explore frontostriatal network dysfunction in unilateral...     

斑蝥酸钠维生素B6联合化疗对肺癌疗效分析

目的：观察化疗联合斑蝥酸钠维生素B6治疗肺癌的效果。方法：选取2017年1月至2019年10月池州市人民医院收治的晚期肺腺癌患者66例作为研究对象，按照用药方法不同分为对照组与观察组，每组33例，对照组通过顺铂联合培美曲塞二钠方案化疗治疗，观察组在此基础上联合斑蝥酸钠维生素B6治疗，比较2组治疗效果，以及用药前后生命质量评分（FACT-L）、癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE）、细胞角蛋白19片段（CA21-1）等改变以及药物不良反应。结果：与对照组比较，观察组的近期治疗效果更优（P<0.05）；治疗后观察组生命质量评分明显高于对照组（P<0.05）；2组CEA、NSE、CA21-1等水平比较差异有统计学意义（P<0.05）；观察组不良反应发生率明显低于对照组（P<0.05）。结论：以化疗联合斑蝥酸钠维生素B6治疗能够使肺癌患者的生命质量明显提升，降低不良反应发生率，使肺癌标志性指标明显改善，对延长患者的生存时间有积极意义。     

Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients

Multidrug resistance due to facilitated drug efflux mediated by ATP-binding cassette (ABC) transporters is a main cause for failure of cancer therapy. Genetic polymorphisms in ABC genes affect the disposition of chemotherapeutics and constitute important biomarkers for therapeutic response and toxicity. Here we correlated germline variability in ABC transporters with disease-specific survival (DSS) in 960 breast cancer (BRCA), 314 clear cell renal cell carcinoma and 325 hepatocellular carcinoma patients. We find that variant burden in ABCC1 is a strong predictor of DSS in BRCA patients, whereas candidate polymorphisms are not associated with DSS. This association is highly drug-specific for subgroups treated with the MRP1 substrates cyclophosphamide (log-rank p = 0.0011) and doxorubicin (log-rank p = 0.0088) independent of age and tumor stage, whereas no association was found in individuals treated with tamoxifen (log-rank p = 0.13). Structural mapping of significant variants revealed multiple variants at residues involved in protein stability, cofactor stabilization or substrate binding. Our results demonstrate that BRCA patients with high variant burden in ABCC1 are less prone to respond appropriately to pharmacological therapy with MRP1 substrates, thus incentivizing the consideration of genomic germline data for precision cancer medicine.     

丙戊酸钠通过EGFR下调CD44表达抑制胶质瘤细胞生长

目的:探讨丙戊酸钠通过抑制A172胶质瘤细胞表皮生长因子受体（epidermal growth factor receptor，EGFR）的活化，下调CD44表达，进而调节细胞生长的机制。方法:实时荧光定量PCR和Western blot检测A172胶质瘤细胞中CD44以及siRNA下调CD44表达的情况，MTT检测CD44和丙戊酸钠对细胞生长的影响，Western blot检测丙戊酸钠对细胞中p-EGFR、EGFR和CD44表达影响。结果:丙戊酸钠抑制A172胶质瘤细胞生长，并具有浓度依赖性。A172胶质瘤细胞表达CD44，siRNA下调CD44表达后，细胞生长较正常组显著减缓。活化EGFR促进A172胶质瘤CD44蛋白表达，而EGFR的抑制剂Lapatinib可显著抑制上述效应。丙戊酸钠抑制EGFR磷酸化，下调CD44蛋白表达。结论:丙戊酸钠抑制A172胶质瘤细胞的生长。抑制A172胶质瘤细胞中EGFR的活化，下调CD44的表达，是丙戊酸钠抑制胶质瘤细胞生长的其中一个机制。     

Plastin 1 drives metastasis of colorectal cancer through the IQGAP1/Rac1/ERK pathway

Tumor metastasis is the dominant cause of death in colorectal cancer (CRC) patients, and it often involves dysregulation of various cytoskeletal proteins. Plastin 1 (PLS1) is an actin‐bundling protein that has been implicated in the structure of intestinal epithelial microvilli; however, its role in CRC metastasis has not yet been determined. In this study, we demonstrated that PLS1 is highly expressed in 33.3% (45/135) of CRC patients and is correlated with lymph node metastasis and poor survival. In in vitro and in vivo experiments, PLS1 induced the migration and invasion of CRC cells and the metastases to the liver and lung in mice. Moreover, the expressions of key factors for CRC metastases, matrix metalloproteinase (MMP) 9 and 2, were enhanced by PLS1, which was dependent on phosphorylating ERK1/2 activated by IQGAP1/Rac1 signaling. The connection between these signals and PLS1 was further confirmed in CRC tissues of patients and the metastatic nodules from a mouse model. These findings suggest that PLS1 promotes CRC metastasis through the IQGAP1/Rac1/ERK pathway. Targeting PLS1 may provide a potential approach to inhibit the metastasis of CRC cells.     

虚拟仿真实验教学项目在临床医学等专业学生培养中的应用

合理设置课程对于人才培养质量起到关键性作用。在临床医学人才培养的课程体系中融入虚拟仿真实验教学项目，是人才培养以及信息化与高等教育实践教学深度融合的内在要求。基于我校虚拟仿真实验教学的开展情况，对虚拟仿真实验教学项目如何在医学生培养中发挥作用进行归纳和总结，包括如何选择虚拟项目，如何融入课程体系等，并以问卷等方式对其教学效果进行调查。结果显示：大部分学生认为虚拟仿真实验教学项目的应用有助于知识的拓展，有助于提升学习效果，有助于培养临床医学人才的临床思维和科研素质，有助于培养自主学习和终身学习能力，有助于掌握信息技术等相关技能。但如何更好地实现虚实融合等问题值得我们进一步的探索和研究。     

鼻咽癌放疗导致海马损伤及认知功能障碍研究进展

放射性认知功能障碍是鼻咽癌患者放疗后常见并发症,主要与神经发生障碍、胶质细胞损伤、血管损伤和细胞因子表达异常有关。随着医学的进步,功能磁共振可以提示认知障碍的早期病变,屏蔽海马及药物治疗(美金刚、多奈哌齐、贝伐单抗等)等方法可改善放射性认知障碍。本文总结了放射性认知障碍的发病机制、影像学、放疗剂量学和治疗方法。     

基于手机应用程序的居家用药管理对肺移植受者依从性及生存质量的影响

目的探讨"肺病与移植管理"App结合1日药盒用药法居家用药管理方案对肺移植受者自我管理、用药依从性及生存质量的影响。 方法选取2019年1至6月无锡市人民医院肺移植中心门诊随访的73例肺移植受者进行自我管理、用药依从性及生存质量的问卷调查。成立用药随访管理小组，制订肺移植受者居家用药管理方案。予肺移植受者"肺病与移植管理"APP结合1日药盒用药法居家用药管理方案干预3个月后再次对其进行问卷调查，比较干预前后受者自我管理、自我效能、用药依从性及生存质量差异。采用配对t检验比较"肺病与移植管理"App结合1日药盒用药法居家用药管理方案干预前后肺移植受者自我管理、自我效能、用药依从性和生存质量得分，P<0.05为差异有统计学意义。 结果干预3个月后，受者自我管理、认知性症状管理实践、用药依从性、生存质量及生理方面生存质量得分分别为(37±7)、(16±3)、(7.0±1.0)、(154±26)和(77±14)分，均高于干预前[(33±9)、(13±6)、(6.5±1.1)、(141±30)和(67±17)分]，差异均有统计学意义(t＝-0.609、-3.383、-12.864、-2.818和3.586，P均<0.05)。干预前后受者自我效能、运动锻炼、与医师的沟通、症状管理、疾病共性管理和心理方面生存质量得分差异均无统计学意义(t＝-1.972、-0.609、-1.486、-1.747、-1.746和1.487，P均>0.05)。干预前用药依从性好、中和差受者分别有16、41和16例，干预后分别为27、40和6例。 结论基于移动健康平台制订的居家用药管理方案可提高肺移植受者自我管理、用药依从性及生理方面的生存质量。     

The Comprehensive Analysis of Efficacy and Safety of CalliSpheres^® Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center,Cohort Study

This study aimed to investigate the efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization (DEB-TACE) in treating Chinese patients with liver cancer. A total of 367 liver cancer patients from 24 medical centers were consecutively enrolled in this multiple-center, prospective cohort study, including 275 hepatocellular carcinoma (HCC) cases, 37 intrahepatic cholangiocarcinoma (ICC) cases, and 55 secondary liver cancer cases. All the patients received CalliSpheres^® DEB-TACE treatment. Treatment response, overall survival (OS), change of liver function, and adverse events (AEs) were assessed. DEB-TACE treatment achieved 19.9% complete response (CR) and 79.6% objective response rate (ORR), with mean OS of 384 days [95% confidence interval (CI): 375–393 days]. CR and ORR were both higher in HCC patients compared with primary ICC patients and secondary liver cancer patients, while no difference was discovered in OS. Portal vein invasion was an independent risk factor for CR, while portal vein invasion, previous conventional TACE (cTACE) treatment, and abnormal blood creatinine (BCr) were independent risk factors for ORR. In addition, largest nodule size 5.0 cm, abnormal albumin (ALB), and abnormal total bilirubin (TBIL) independently correlated with unfavorable OS. Most liver function indexes were recovered to baseline levels at 1–3 months after DEB-TACE. Common AEs were pain, fever, vomiting, and nausea; most of them were at mild grade. CalliSpheres^® DEB-TACE is efficient and well tolerated in Chinese liver cancer patients. Portal vein invasion, previous cTACE treatment, largest nodule size, abnormal BCr, ALB, and TBIL correlate with worse prognosis independently.